Skip to main content
NANO MRNA Co.,Ltd. logo

NANO MRNA Co.,Ltd. — Investor Relations & Filings

Ticker · 4571 ISIN · JP3651120002 LEI · 529900L2VA2GIFZQTG17 T Professional, scientific and technical activities
Open in API
Filings indexed 71 across all filing types
Latest filing 2026-06-01 Share Issue/Capital Cha…
Country JP Japan
Listing T 4571

About NANO MRNA Co.,Ltd.

https://www.nanomrna.co.jp/

NANO MRNA Co., Ltd. is a biotechnology firm that operates as a platform company and an IP Generator specializing in mRNA-based medicine. The company focuses on creating and out-licensing intellectual property for novel therapeutics by connecting drug discovery seeds with medical and development needs. It leverages a proprietary drug delivery system (DDS) based on micellar nanoparticle technology to advance its pipeline. Key clinical programs include an mRNA therapy for osteoarthritis (RUNX1 mRNA) and an antisense oligonucleotide (ASO) for glioblastoma (TUG1 ASO). Evolving from its predecessor, NanoCarrier, the company combines a legacy of R&D in nanoparticle technology with a strategic focus on RNA drug discovery. It also co-developed and markets Comlex®, an antibacterial agent for ear, nose, and throat conditions.

Recent filings

Filing Released Lang Actions
第22回新株予約権（行使価額修正条項付）の月間行使状況に関するお知らせ
Share Issue/Capital Change Classification · 75% confidence The document is a monthly notification of the exercise status of the company’s 22nd share subscription rights, detailing the number of new shares issued upon option exercises and remaining unexercised. This constitutes an announcement concerning share issuance (capital change) rather than a full financial report or routine earnings release. Under our taxonomy, it best fits “Share Issue/Capital Change” (SHA).
2026-06-01 Japanese
取締役の報酬額改定および譲渡制限付株式報酬制度の改定に関するお知らせ
Remuneration Information Classification · 90% confidence The document is a corporate announcement regarding revisions to director (取締役) remuneration limits and amendments to the restricted stock compensation plan. It details compensation structures for top executives and the changes to be proposed at the upcoming annual shareholders meeting. This aligns exactly with the definition of “Remuneration Information” (DEF 14A), which covers reports detailing compensation for top executives and directors.
2026-05-22 Japanese
2026年3月期決算説明会資料
Investor Presentation Classification · 88% confidence The document is a slide deck titled “2026年3月期 決算説明会” containing consolidated income statements, balance sheets, cash flow statements, future outlook, strategic initiatives, and investor‐focused narrative. It is a detailed presentation for investors rather than a brief earnings release or formal annual report filing. Therefore, it best fits the Investor Presentation category.
2026-05-19 Japanese
第22回新株予約権（行使価額修正条項付）の月間行使状況に関するお知らせ
Regulatory Filings
2026-05-01 Japanese
（訂正）「戦略子会社NANO MRNAによるLuna RD株式会社の株式取得（子会社化）による子会社の異動に関するお知らせ」の一部訂正について
Regulatory Filings
2026-04-24 Japanese
戦略子会社NANO MRNAによるLuna RD株式会社の株式取得（子会社化）による子会社の異動に関するお知らせ
Regulatory Filings
2026-04-24 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.